References selected and published in this document are representative and not all-inclusive. To provide clinicians with a comprehensive set of data, whenever deemed appropriate or when published, the abso- lute risk difference and number needed to treat or harm will be provided in the guideline, along with confidence intervals (CIs) and data related to the relative treatment effects such as odds ratio (OR), relative risk, hazard ratio (HR), or incidence rate ratio. The focus of this guideline is the safe, appropriate, and efficacious performance of PCI. The risks of PCI must be balanced against the likelihood of improved survival, symp- toms, or functional status. This is especially important in patients with SIHD. 1.2. Organization of the Writing Committee The committee was composed of physicians with expertise in interventional cardiology, general cardiology, critical care cardiology, cardiothoracic surgery, clinical trials, and health services research. The committee included representatives from the ACCF, AHA, and SCAI. 1.3. Document Review and Approval This document was reviewed by 2 official reviewers nomi- nated by the ACCF, AHA, and SCAI, as well as 21 individual content reviewers (including members of the ACCF Interven- tional Scientific Council and ACCF Surgeons Scientific Council). All information on reviewers RWI was distributed to the writing committee and is published in this document (Appendix 2). This document was approved for publication by the governing bodies of the ACCF, AHA, and SCAI. 1.4. PCI Guidelines: History and Evolution In 1982, a 2-page manuscript titled Guidelines for the Performance of Percutaneous Transluminal Coronary Angio- plasty was published in Circulation.4 The document, which addressed the specific expertise and experience physicians should have to perform balloon angioplasty, as well as laboratory requirements and the need for surgical support, was written by an ad hoc group whose members included Andreas Gru ntzig. 